Steven Harper, Jesus Ontoria, Federica Ferrigno, Simona Ponzi, Emanuela Nizi, Ilaria Biancofiore, Savina Malancona, Giacomo Paonessa, Alberto Bresciani, Edith Monteagudo, Annalise Di Marco and Vincenzo Summa
IRBM-Science Park, Via Pontina km 30,600, Pomezia, 00071 Rome, Italy
Epigenetic effects – often modulated by histone deacetylase (HDAC) enzymes– can result in dramatic changes to gene expression, and consequently HDAC inhibitors have evolved into a major class of anti-cancer agents. However, the potential to modulate gene expression by HDAC inhibition is also stimulating increasing interest for non-oncological indications, including rare and neglected diseases such as muscular dystrophies, hemoglobinopathies and parasitic diseases . The present talk will provide a brief overview of our efforts and results in some of these fields, where several related but highly complementary selective series of inhibitors have been discovered.
 Ontoria, J.M. et al. Discovery of a Selective Series of Inhibitors of Plasmodium falciparum HDACs, ACS Med. Chem. Lett., 2016, 7 (5), pp 454–459